Eloralintide History and Updates

27 events · 2025 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
27
Trial Milestones
0
Pivotal Publications
Eloralintide — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications2025202620272028Trial: NCT07589608 2026-06-30 → 2027-09-30 (primary completion)Trial: NCT07369011 2026-02-10 → 2028-03-31 (primary completion)Trial: NCT07392190 2026-02-10 → 2028-06-30 (primary completion)Trial: NCT07353931 2026-02-09 → 2028-03-31 (primary completion)Trial: NCT07321886 2026-02-06 → 2028-03-31 (primary completion)Trial: NCT07282600 2025-12-15 → 2028-01-31 (primary completion)Trial: NCT07215559 2025-10-16 → 2027-03-31 (primary completion)Trial: NCT06916091 2025-04-21 → 2025-09-09 (primary completion)Trial: NCT06916065 2025-04-09 → 2026-01-19 (primary completion)today (2026-06-08)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-08Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Eloralintide since 2025, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07589608
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Ov
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT07215559
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type
Primary completion· ClinicalTrials.gov
Phase 2 primary completion: NCT07589608
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Ov
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07369011
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07353931
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Primary completion· ClinicalTrials.gov
Phase 3 primary completion: NCT07392190
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Past events

2026
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07369011
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07392190
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07353931
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07321886
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Phase 1 primary completion: NCT06916065
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
2025
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT07282600
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Trial started· ClinicalTrials.gov
Phase 2 trial started: NCT07215559
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type
Trial started· ClinicalTrials.gov
Phase 1 trial started: NCT06916065
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.